Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B

查看全文 作　　者：Fehmi [1]Ates;Mehmet [2]Yalnlz;Saadet [3]Alan

机构地区：[1]School of Medicine Department of Gastroenterology Mersin University,33070 Mersin Turkey;[2]School of Medicine Department of Gastroen-terology Firat University,23119 Elazlg Turkey;[3]Department of Pathology Malatya Government Hospital,44300 Malatya Turkey

出　　处：《World Journal of Gastroenterology》索引2011年第17卷第40期,共6页

摘　　要：AIM: To evaluate the impact of liver steatosis upon response to given therapy in chronic hepatitis B (CHB) patients. METHODS: 84 consecutive CHB patients treated with 48-wk PEGylated interferon (PEG-IFN) therapy were enrolled. Baseline characteristics and sustained viral response (SVR) to PEG-IFN therapy were evaluated. RESULTS:Mean body mass index (BMI) was 27.36 ± 4.4 kg/m 2 . Six (7.1%) had hypertension and three (3.5%) had diabetes mellitus. Steatosis was present in 22.6% (19/84) of liver biopsy samples. Age, BMI, and triglyceride levels of the patients with hepatic steatosis were significantly higher than those without hepatic steatosis (P < 0.05). SVR to PEG-IFN therapy was 21.4% (18/84). Sixteen of these 18 CHB patients with SVR (88.9%) did not have any histopathologically determined steatosis. On the other hand, only two of the 19 CHB patients with hepatic steatosis had SVR (10.5%). Although the SVR rate observed in patients without steatosis (16/65, 24.6%) was higher compared to those with steatosis (2/19, 10.5%), the difference was not statistically significant (P > 0.05). CONCLUSION:Occurrence of hepatic steatosis is significantly high in CHB patients and this association leads to a trend of decreased, but statistically insignificant, SVR rates to PEG-IFN treatment. 关键词：慢性乙型肝炎脂肪肝聚乙二醇干扰素患者治疗 SVR PEG

相关文献

参考文献（26）
引证文献（16）
耦合文献（0）

参考文献(26)

引证文献(16)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B

参考文献(26)

引证文献(16)

用户提示